Analysts Set Avid Bioservices Inc (CDMO) PT at $4.00

Shares of Avid Bioservices Inc (NASDAQ:CDMO) have received a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $4.00.

CDMO has been the topic of several analyst reports. Zacks Investment Research cut Avid Bioservices from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. First Analysis started coverage on Avid Bioservices in a research report on Tuesday, March 13th. They set an “overweight” rating and a $4.00 price target on the stock. Wells Fargo started coverage on shares of Avid Bioservices in a research report on Thursday, March 15th. They issued an “outperform” rating on the stock. Noble Financial restated a “buy” rating on shares of Avid Bioservices in a research report on Friday, January 5th. Finally, ValuEngine cut shares of Avid Bioservices from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd.

In related news, Director Mark R. Bamforth acquired 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were bought at an average cost of $2.25 per share, for a total transaction of $112,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.53% of the stock is currently owned by corporate insiders.



Shares of CDMO opened at $3.20 on Monday. Avid Bioservices has a twelve month low of $2.24 and a twelve month high of $5.78.

Avid Bioservices (NASDAQ:CDMO) last announced its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.09). Avid Bioservices had a negative net margin of 46.62% and a negative return on equity of 57.49%. The company had revenue of $6.82 million for the quarter, compared to the consensus estimate of $8.95 million. equities analysts anticipate that Avid Bioservices will post -0.63 earnings per share for the current year.

The business also recently disclosed a dividend, which was paid on Monday, April 2nd. Investors of record on Monday, March 19th were given a $0.6563 dividend. The ex-dividend date was Friday, March 16th.

TRADEMARK VIOLATION NOTICE: “Analysts Set Avid Bioservices Inc (CDMO) PT at $4.00” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2018/04/12/analysts-set-avid-bioservices-inc-cdmo-pt-at-4-00.html.

Avid Bioservices Company Profile

Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply